Introduction
============

Congestive heart failure (CHF) is one of common diseases found in dialysis patients. When present at the initiation of dialysis, CHF is an adverse, independent, prognostic indicator of mortality, and hypertension is known as its major risk factor in dialysis patients.\[[@B1]\] One of the important goals of blood pressure control in these patients is the prevention of excessive weight gain (edema) between successive episodes of dialysis.\[[@B2]\]

Diuretics are useful in the treatment of hypertension and edema in renal patients. However, patients with chronic renal insufficiency also have diuretic resistance. Causes of the resistance that have been suggested are decreased numbers of functioning nephrons, decreased tubular delivery of diuretics, and augmented sodium reabsorption in the distal tubules.\[[@B3][@B4]\] To circumvent such limitations, combination diuretic treatment is recommended; its aim is to act on different nephron segments so that each diuretic might enhance the response of the other.\[[@B5]\]

If combination diuretic therapy were effective for the treatment of edema in dialysis patients, it would improve the prognosis for those with CHF. However, it is difficult to evaluate the efficacy of diuretic combination in patients under dialysis, as their hemodynamic states vary with dialysis time and the intervals between episodes of dialysis. We therefore performed a crossover study to evaluate the efficacy of furosemide alone and in combination with hydrochlorothiazide in patients with end stage renal disease (ESRD: creatinine clearance \< 10 ml/min/1.73 m^2^) before the initiation of dialysis therapy.

Methods
=======

Subjects
--------

We recruited 10 patients with creatinine clearance less than 10 ml/min/1.73 m^2^ who had never undergone any renal replacement therapy such as hemodialysis or peritoneal dialysis. The patients had been followed up for known renal failure as outpatients. When the disease status had advanced to the end-stage, they were admitted and the present study was performed just before their first hemodialysis.

The patients were aged 56--67 years (eight men, two women) with underlying diabetes mellitus (five patients) or suspected glomerulonephritis (five patients: [Table 1](#T1){ref-type="table"}). Severe proteinuria (\>1,000 mg/day) was a common finding, regardless of the patient\'s underlying disease. All patients were taking enalapril or nifedipine to control their hypertension. Although the dosage regimens of anti-hypertensive agents were kept constant throughout the study period, prescribed diuretics---if any---were withheld at least 48 h before the initiation of the study. The patients gave written informed consent to this trial after full explanation of the protocol. However, those who needed emergency hemodialysis for pulmonary edema, hyperkalemia with abnormal electrocardiogram, severe metabolic acidosis, or uremia were precluded. The Institutional Review Board of Samsung Medical Center approved the research protocol.

Study Design
------------

Patients were admitted at least two days before the study and a low salt diet was prescribed. Diuretics were discontinued on the day of admission without changing the other medications. A randomized crossover study of furosemide monotherapy versus coadministration of furosemide and hydrochlorothiazide (PK/PD) was performed with a 24 h washout period. The scheme of the study is summarized as: first baseline data collection (urine collection for 24 h); diuretic PK/PD study (first phase, 24 h); washout (24 h); second baseline data collection (24 h); diuretic PK/PD study (second phase, 24 h). One hundred and sixty milligrams of furosemide, dissolved in 100 ml of 5% dextrose solution, was intravenously infused into the patients for 30 minutes starting at 09:00 on each of the two study phases. During coadministration, which was randomly allocated into the first or second phase, 25 mg of oral hydrochlorothiazide was given four times every 6 h beginning at 09:00. Urine was collected at intervals of 0--3, 3--6, 6--12 and 12--24 h for both of the study phases, as well as for baseline phases. As the washout period between the phases could not be allowed long enough because of the patients\' disease status, 24 h urine collection for baseline data was performed one day before each study phase. This was also to examine whether the degree of electrolyte excretion was influenced by the previous diuretic medication, i.e. the appropriateness of the washout interval, which could not be given for long enough in these ESRD patients.

To evaluate whether the pharmacokinetics of furosemide were changed by thiazide administration, 10 ml of venous blood was drawn into heparinized tubes at 0, 0.5, 1, 3, 6, 12 and 24 h after the start of furosemide infusion in both of the study phases. The plasma, separated immediately after sampling, was stored −70℃ until the furosemide concentration assay could be performed.

Analysis of Urine and Plasma Samples
------------------------------------

We measured urine sodium and urea by ion-selective methods (Synchron CX3, Beckman, Germany) and creatinine in blood and urine by Jaffe\'s method (Hitachi 747, Hitachi, Japan). Protein in 24 h urine samples was measured by the pyrogallol red-molybdate complex method (Hitachi 747, Hitachi, Japan). Furosemide concentrations in urine and plasma were measured by high performance liquid chromatography (HPLC) as described elsewhere.\[[@B6]\]

Plasma Furosemide Pharmacokinetics
----------------------------------

The area under the curve (AUC), plasma clearance rates and half-life of furosemide in plasma were obtained by the non-compartmental analysis method using PkCalc.\[[@B7]\] The urinary excretion rate of furosemide was calculated on the basis of the urine concentration and volume per collection time interval.

Statistical Tests
-----------------

To compare the effects between monotherapy and coadministration, pharmacokinetic parameters, 24 h urine volumes and excreted amounts of sodium and chloride were tested by Wilcoxon signed rank tests. Changes in electrolyte excretion in comparison with the baseline values after each phase were also tested by Wilcoxon signed rank tests.

Pharmacodynamic Modeling
------------------------

We performed a mixed-effects model analysis using NONMEMâ (Version 5.0)\[[@B8]\] to detect the influence of hydrochlorothiazide that may not be found significant by the statistical tests mentioned above. The fractional excretion of sodium (FeNa), which is less influenced by diet and water intake, was used as a surrogate endpoint and its relationship with urine furosemide excretion rate was assessed. To find the appropriate model, we compared linear, Emax and sigmoid Emax models. The existence of hysteresis was also tested by adding cumulative amount of excreted furosemide as a covariate.\[[@B9]\] As the Emax model was better than the linear and sigmoid Emax models, further evaluation of pharmacodynamic parameters, such as Emax, ER~50~ (the excretion rate which shows effect equivalent to 50% of Emax) and E~0~ (baseline FeNa value) and their distribution, was performed. Serum creatinine concentrations and the addition of thiazide (1 for thiazide addition, 0 for furosemide only) were tested for their contribution to the pharmacodynamic parameters. Inter-individual differences were estimated with an exponential model and the residual error with a proportional model.

Difference in the minimal value of objective function (MVO) was used as a selection criterion between models. The level of statistical significance was set at *P* \< 0.01 (a decrease in the MVO of \> 6.6).

Results
=======

Urine volume and excreted amounts of sodium and chloride
--------------------------------------------------------

The 24 h urine volume increased significantly following furosemide monotherapy. Although the increase was also significant in coadministration, there was no statistically significant difference between monotherapy and coadministration ([Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). The amounts of excreted sodium, chloride and urea were greater in diuretic than in baseline phases. However, no significant difference between monotherapy and coadministration was apparent ([Table 2](#T2){ref-type="table"}). The same results were observed for urine volumes and excreted amounts of electrolytes and urea.

Pharmacokinetics of furosemide
------------------------------

The pharmacokinetic parameters of monotherapy and coadministration (in parentheses) were 86.7 ± 49.1 (87.8 ± 37.9) µg/ml per hour for AUC~24~, 39.2 ± 18.4 (35.3 ± 13.9) ml/min for plasma clearance, 2.47 ± 0.64 (3.01 ± 0.60) h for the half-life and 5.93 ± 3.87 (6.50 ± 4.88) % for the excreted furosemide fraction. Coadministration thus had no significant effects on furosemide pharmacokinetics.

Pharmacodynamic Modeling
------------------------

Using the Emax model, the influence of hydrochlorothiazide coadministration was assessed for Emax and ER~50~. No contributable covariates were found ([Table 3](#T3){ref-type="table"}). Final estimated fixed effect parameters; their inter-individual variations and residual errors are shown in [Table 4](#T4){ref-type="table"}. The standard error of ER~50~ estimated with \$COV was very large (90% C.I. included 0). We guess this negative 90% C.I. may be simply because of the large variation in the ER~50~ estimates, which cannot be negative. Some of the standard errors of the estimated θ or ω were very large. The baseline FeNa observed was positively correlated with serum creatinine concentrations and this is known to result through the compensation of the remaining nephrons. To consider the daily fluctuation of baseline FeNa, the term IOV (inter-occasional variability) was also added. Neither counter-clockwise nor clockwise hysteresis was found. We also screened the relation between Emax and ER~50~ with the \$OMEGA BLOCK option in the NONMEM control file, but it did not improve the scatter plot or MVO. No covariates significantly influencing Emax or ER~50~ were found.

Discussion
==========

Study Design
------------

This study was performed to explore the effect of thiazide diuretics on furosemide therapy in patients with ESRD (creatinine clearance \< 10 ml/min/1.73 m^2^). A beneficial effect of such coadministration in patients undergoing hemodialysis has been proposed.\[[@B10]\] However, with the rapid hemodynamic changes occurring during dialysis, it is not easy to obtain reliable data in such patients. We therefore tested the effect of diuretic coadministration in patients with ESRD who had not undergone renal replacement therapy.

Furosemide has a smaller hepatic clearance fraction than other loop diuretics. This makes its diuretic effect closely correlated with renal function and last longer than other agents.\[[@B11]\] As Fliser et al.\[[@B10]\] used 50 mg torasemide, which is about three times as potent as furosemide,\[[@B12]\] we administered 160 mg furosemide for comparability.

Synergistic mechanisms of thiazide and loop diuretics have been proposed that rebound augmentation of sodium reabsorption in the distal renal tubule with the declining effects of loop diuretics might be inhibited by thiazide.\[[@B13][@B14][@B15]\] In accordance with this postulate, we administered hydrochlorothiazide in divided doses, not in a single dose, after infusion of furosemide. Although the interval needed for the complete washout of hemodynamic effects caused by diuretics may be longer, we established it at 48 h (including a second baseline data collection period) for the safety and compliance of our patients. Baseline data obtained one day before each phase showed that this 48 h washout was appropriate, and there were no significant differences in the baseline data of monotherapy or coadministration ([Table 2](#T2){ref-type="table"}).

Pharmacodynamic Modeling
------------------------

We performed pharmacodynamic analysis to evaluate whether there was any effect of coadministered thiazide that might have been obscured in the widely dispersed data. Because the direct action of loop diuretics and thiazide involves the renal tubule, urinary diuretic excretion rate is generally regarded as a better predictor of tubular diuretic concentration than serum concentration. Several methods have been proposed for the pharmacokinetic-pharmacodynamic modeling of loop diuretics. Recent reports have used the so-called physiological model (indirect effect model) using differential equations to describe the time--effect relation. However, this was hard to apply to our data because of the relatively small number of observations caused by long sampling intervals.

Observing raw data, we found overt counter-clockwise hysteresis in three of the 10 patients. However, the structural model with a hysteresis term (Model No. 5 in [Table 3](#T3){ref-type="table"}) was not helpful in decreasing the MVO or improving the appearance of scatter plots. This seems to have been caused by the influence of the other seven patients\' data. The longer urine sampling intervals compared with those of previous studies in healthy individuals also influenced our ability to delineate the hysteresis. Although the pharmacodynamic model proposed here does not present a detailed explanation of the time course of the effect or the pharmacokinetics or pharmacodynamics of furosemide treatment, it seems worthwhile to apply mixed effect modeling methods for the in-depth investigation of pharmacodynamic interactions in patients.

We could not find any significant effect of hydrochlorothiazide added to furosemide treatment in our patients. Pharmacodynamic analysis using a mixed effect model also failed to detect any influence of hydrochlorothiazide. Although the effectiveness of diuretic combination therapy in patients with chronic renal insufficiency has been reported by some authors,\[[@B10][@B16]\] only four of the 10 subjects in Fliser\'s report\[[@B10]\] and only three of the 19 subjects in Knauf\'s report\[[@B16]\] were patients with ESRD. Neither of the two reports mentioned the degree of proteinuria in their subjects. In contrast to these reports, all of the ESRD subjects enrolled in the present study had a creatinine clearance less than 10 ml/min/1.73 m^2^ and showed significant proteinuria (1152--7425 mg/day). We suggest that the decreased number of functioning nephrons in patients with ESRD and the lower unbound concentration of diuretics in the renal tubule caused by massive proteinuria have resulted in such a lack of efficacy of diuretic combination therapy.
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![Furosemide excretion rate (closed circles) and FeNa (fractional excretion of sodium, open circles) observed with and without hydrochlorothiazide treatment. (Means ± S.D.)](tcp-25-28-g001){#F1}

###### Demographic profile of the patients with ESRD

![](tcp-25-28-i001)

  Patient No.   Age (years)   Sex   Renal disease   SCr^b^ (mg/dl)   CLCr^c^ (ml/min/1.73 m^2^)   24 hour urine protein (mg/24 hr)   Antihypertensive drugs
  ------------- ------------- ----- --------------- ---------------- ---------------------------- ---------------------------------- ------------------------
  1             56            M     DM^a^           8.2              6.3                          3190                               enalapril
  2             56            M     GNS^a^          17.7             2.5                          3042                               enalapril
  3             48            M     DM^a^           7.7              8.1                          1152                               enalapril
  4             68            M     DM^a^           8.1              8.1                          8970                               enalapril
  5             42            M     GNS^a^          11.2             4.1                          1386                               nifedipine
  6             49            F     GNS^a^          14.0             1.2                          2465                               nifedipine
  7             56            M     DM^a^           8.1              5.3                          3500                               enalapril
  8             57            M     DM^a^           10.9             7.0                          7425                               enalapril
  9             52            F     GNS^a^          10.8             2.3                          2150                               nifedipine
  10            67            M     GNS^a^          11.5             3.9                          5200                               enalapril

^a^DM, diabetic nephropathy; GNS, glomerulonephritis suspected. ^b^SCr, serum creatinine. ^c^CLCr, creatinine clearance.

###### Cumulative 24 h urine volume, sodium, chloride and creatinine excretions in patients with ESRD after furosemide monotherapy and coadministration of furosemide and hydrochlorothiazide (Means ± S.D.)

![](tcp-25-28-i002)

  Parameters of 24 h Urine   Monotherapy (baseline)           Coadministration (baseline)
  -------------------------- -------------------------------- --------------------------------
  Volume (ml)                2094 ± 810^\*^ (1643 ± 529)      2164 ± 701^\*^ (1595 ± 509)
  Sodium (mEq)               149.4 ± 59.5^\*^ (89.6 ± 28.2)   151.7 ± 60.8^\*^ (75.8 ± 39.9)
  Chloride (mEq)             154.6 ± 66.5^\*^ (87.2 ± 41.1)   142.8 ± 61.2^\*^ (64.6 ± 35.3)
  Creatinine (mg)            850.7 ± 288.5 (910.5 ± 311.8)    821.3 ± 258.9 (856.7 ± 233.5)

^\*^: p \< 0.05 when compared with baseline (E~0~). None of the parameters showed difference between monotherapy and coadministration.

###### Screening of effect models and its covariates for furosemide excretion rate and FeNa. The model 3 (Emax model) was found most appropriate to explain the pharmacodynamic relationship
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        Model Structure                                                                                                                                     MVO       p-Value   Explanation
  ----- --------------------------------------------------------------------------------------------------------------------------------------------------- --------- --------- ------------------------------------------------------------
  1\.   *Slope* = θ~1~, *Intercept* = θ~2~\                                                                                                                 636.566             Simple Linear model.
        *E* = *Slope* × *FuER* + *Intercept*                                                                                                                                    

  2\.   *E* max = θ~1~,*ER*~50~ = θ~2~ ,*E*~0~ = θ~3~\                                                                                                      560.896   p\<0.01   Emax model.\
        $\mathit{E} = \frac{E\text{\;max} \times \textit{FuER}}{\textit{ER}_{50} + \textit{FuER}} + \mathit{E}_{0}$                                                             Baseline value without consideration of SCr

  3\.   *E* max = θ~1~,*ER*~50~ = θ~2~,\                                                                                                                    531.174   p\<0.01   Emax model.\
        *E*~0~ = θ~3~ × *SCr*\                                                                                                                                                  Baseline value increase in proportion to SCr
        $\mathit{E} = \frac{E\text{\;max} \times \textit{FuER}}{\textit{ER}_{50} + \textit{FuER}} + \mathit{E}_{0}$                                                             

  4\.   *E* max = θ~1~,*ER*~50~ = θ~2~, γ = θ~3~\                                                                                                           534.489             Sigmoid Emax model.\
        *E*~0~ = θ~4~ × *SCr*\                                                                                                                                                  No improvement in MVO compared with model No. 3
        $\mathit{E} = \frac{\mathit{E}\text{\;max} \times \textit{FuER}^{\gamma}}{{\textit{ER}_{50}}^{\gamma} + \textit{FuER}^{\gamma}} + \mathit{E}_{0}$                       

  5\.   *E* max = θ~1~,*ER*~50~ = θ~2~, *E*~0~ = θ~3~ × *SCr*\                                                                                              529.939             Emax model testing the existence of hysteresis if any.\
        $\textit{Hys} = \theta_{4} \times {\sum\limits_{0}^{\mathit{t}}\textit{Furosemide\_Excretion}}$\                                                                        No improvement in MVO compared with model No. 3
        $\mathit{E} = \frac{\mathit{E}\text{\;max} \times \textit{FuER}}{\textit{ER}_{50} \cdot \mathit{e}^{\textit{Hys}} + \textit{FuER}}$                                     

  6\.   *E* max = θ~1~,*ER*~50~ = θ~2~ + *Thia* × θ~3~,\                                                                                                    534.415             Influence of thiazide addition on Emax of the model No. 3\
        *E*~0~ = θ~4~ × *SCr*\                                                                                                                                                  No improvement in MVO compared with model No. 3
        $\mathit{E} = \frac{E\text{\;max} \times \textit{FuER}}{\textit{ER}_{50} + \textit{FuER}} + \mathit{E}_{0}$                                                             

  7\.   *E* max = θ~1~ + θ~2~ × *Thia*, *ER*~50~ = θ~3~,\                                                                                                   534.009             Influence of thiazide addition on ER50 of the model No. 3\
        *E*~0~ = θ~4~ × *SCr*\                                                                                                                                                  No improvement compared with model No. 3
        $\mathit{E} = \frac{E\text{\;max} \times \textit{FuER}}{\textit{ER}_{50} + \textit{FuER}} + \mathit{E}_{0}$                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FuER: Excretion rate of furosemide.

###### Fixed effect parameters, inter-individual variability and residual errors of the final model
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  Parameters          Meaning                                  Estimated Value   Standard Error   95% Confidence Interval
  ------------------- ---------------------------------------- ----------------- ---------------- -------------------------
  Structural                                                                                      
  θ~1~                Emax                                     17.7              3.01             11.68 - 23.72
  θ~2~                ER~50~                                   5.28              3.18             0 - 11.64
  θ~3~                E~0~=θ~3~ x SCr                          0.693             0.0767           0.54 - 0.85
  Variance                                                                                        
  ω~1~^2^             Interindividual variability for Emax     0.0359            0.0341           0 - 0.104
  ω~2~^2^             Interindividual variability for ER~50~   0.354             0.299            0 - 0.952
  ω~3~^2^             Interindividual variability for E~0~     0.104             0.0508           0.002 - 0.206
  ω~4~^2^ = ω~5~^2^   Interoccasional variability for E~0~     1.06              0.531            0 - 2.122
  σ^2^                Residual variability                     0.0549            0.0133           0.028 - 0.082

\- Final Model -

$$E = \frac{E max \times FuER}{{ER}_{50} + FuER} + E_{0}$$

Emax: Maximum FeNa by furosemide excretion rate, ER~50~: Furosemide excretion rate producing 50% of Emax, E~0~: Baseline FeNa, E: FeNa predicted by Emax model, IOV: Interoccasional variance, OC~1~ or OC~2~: Occasion with or without hydrochlorothiazide, alternates between 1 and 0. FuER: Excretion rate of furosemide, Observed_FeNa: Raw data of FeNa measured in the present study, η~1~: Interindividual difference of Emax, assumed mean value 0 with standard error ω~1~, η~2~: Interindividual difference of ER50, assumed mean value 0 with standard error ω~2~, η~3~: Interindividual difference of E0, assumed mean value 0 with standard error ω~3~, η~4~, η~5~: Interindividual difference of IOV, assumed mean values 0 with standard errors ω~4~ and ω~5~ respectively. ε: Residual variability of E, assumed mean value 0 with standard error σ
